Consequently, the preservation of pulmonary density with exogenous AAT has sparked a debate over a potential change in the main aims of treatment from biochemical efficacy to clinical efficacy, based on emphysema progression evaluated by lung densitometry. The gene discussed is SERPINA1; the disease is pulmonary emphysema.